MAXON
MAXON today announced Cinema 4D Release 17 (R17) , a milestone release of its cornerstone 3D animation, graphics, VFX, visualization, and rendering software. Cinema 4D R17 delivers new, expanded and completely reworked features for exceptional performance allowing creatives to more easily and efficiently manage and create outstanding content. Central to Cinema 4D R17 is the new Take System that provides complete and flexible scene handling to manage render layers and animation variations. Also included are new Lens Distortion tools for improved motion tracking, and completely reworked Spline Tools for a more efficient workflow for manipulating points, lines, tangents, arcs and more.
“MAXON is committed to enriching user experience and productivity,” says Harald Egel, managing partner at MAXON Computer GmbH, “The robust new features and subtle refinements throughout Cinema 4D R17 make this a must-have release.”
Cinema 4D R17 Feature Highlights
At SIGGRAPH 2015 in Los Angeles, August 11 – 13, MAXON will preview the new features in R17. Key highlights include:
Take System: Provides new functionality and flexible scene management allowing artists to create numerous independent takes of a scene and change almost any parameter for variations – all saved in a single scene file, eliminating file management hassles and wasted disk space. The ability to maintain complete versioning and variation control also saves valuable production time.
Lens Distortion Support: Easily generate a distortion profile for any image, e.g., for curved and plunging lines when integrating 3D elements into videos or photos. The intuitive interface also improves functionality to remove distortion for tracking and scene creation, re-apply distortion at render time and offers the option of saving lens settings for future use.
Graph View for Motion Tracker: R17 has a new Graph View that highlights problem track points in a simple-to-use graph and lets users easily remove them from the calculation for improved efficiency.
New Spline Tools: The completely reworked Spline Tools in R17 provide artists with added control for manipulating points, lines, tangents and arcs more intuitively. Users can leverage Boolean operators like Intersect, Subtract, Union, And, Or for an even faster workflow.
Animation Workflow Enhancements: Cinema 4D R17 makes animation faster and more precise. Control F-Curves with weighted tangents with the option of automatically removing overshoot, eliminate Gimbal lock with Euler filtering, and define animation regions using range markers and master animation workflow with new Timeline preferences.
Sculpting Improvements: MAXON introduces dozens of new features in R17 to sculpt with precision and ease. The Sculpt to Pose Morph feature automatically creates morph targets for each sculpt layer, for a quick transition from character design to character animation. The new Edge Detection feature is designed to let users easily sculpt hard-surface models.
Houdini Engine Integration: A seamless integration for Side Effect Software’s Houdini Engine lets users load Houdini Digital Assets (HDA) such as parametric objects, simulations, etc., into Cinema 4D and manipulate them like standard Cinema 4D generators.
SketchUp Integration: Tighter integration in R17 with SketchUp – a 3D modeling program for a wide range of drawing applications – lets creative professionals quickly populate scenes by accessing free, ready-to-use objects created and made available by the SketchUp user community.
Cinema 4D R17 Pricing, Availability and Upgrade Path
Cinema 4D Release 17 is scheduled to ship September 2015. Pricing and upgrade information is available at www.maxon.net . Available for both Mac OS X and Windows. Recommended system requirements .
All trademarks contained herein are the property of their respective owners.
About MAXON
Headquartered in Friedrichsdorf, Germany, MAXON Computer is a developer of professional 3D modeling, painting, animation and rendering solutions. Its award-winning Cinema 4D and BodyPaint 3D software products have been used extensively to help create everything from stunning visual effects in top feature films, TV shows and commercials, cutting-edge game cinematics for AAA games, as well for medical illustration, architectural and industrial design applications. MAXON has offices in Germany, USA, United Kingdom, Canada, France, Japan and Singapore. MAXON products are available directly from the web site and its worldwide distribution channel. MAXON is part of the Nemetschek Group .
View source version on businesswire.com: http://www.businesswire.com/news/home/20150804005757/en/
Contact:
MAXON Computer
Bärbel Buck
press_de@maxon.net
+49-(0)6172-5906643
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum